Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer.
Rahimi A, Morgan HE, Kim DW, Zhang Y, Leitch M, Wooldridge R, Goudreau S, Haley B, Rao R, Rivers A, Spangler AE, Jones RT, Stevenson S, Staley J, Albuquerque K, Ahn C, Neufeld S, Alluri PG, Ding C, Garwood D, Seiler S, Zhao B, Gu X, Timmerman R. Rahimi A, et al. Among authors: alluri pg. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):772-782. doi: 10.1016/j.ijrobp.2021.01.015. Epub 2021 Jan 18. Int J Radiat Oncol Biol Phys. 2021. PMID: 33476737 Free article. Clinical Trial.
Preliminary Results of Multi-Institutional Phase 1 Dose Escalation Trial Using Single-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer.
Rahimi A, Simmons A, Kim DN, Leitch M, Haas J, Gu X, Ahn C, Gao A, Spangler A, Morgan HE, Goudreau S, Seiler S, Farr D, Wooldridge R, Haley B, Bahrami S, Neufeld S, Mendez C, Alluri P, Rao R, Timmerman RD. Rahimi A, et al. Int J Radiat Oncol Biol Phys. 2022 Mar 1;112(3):663-670. doi: 10.1016/j.ijrobp.2021.10.010. Epub 2021 Oct 25. Int J Radiat Oncol Biol Phys. 2022. PMID: 34710523 Free article. Clinical Trial.
Targeting radioresistance and replication fork stability in prostate cancer.
Li X, Baek G, Carreira S, Yuan W, Ma S, Hofstad M, Lee S, Gao Y, Bertan C, Fenor de la Maza MLD, Alluri PG, Burma S, Chen BP, Raj GV, de Bono J, Pommier Y, Mani RS. Li X, et al. Among authors: alluri pg. JCI Insight. 2022 May 9;7(9):e152955. doi: 10.1172/jci.insight.152955. JCI Insight. 2022. PMID: 35349486 Free PMC article.
In Reply to Hannoun-Levi et al.
Rahimi A, Simmons A, Kim DN, Leitch M, Haas J, Gu X, Ahn C, Gao A, Spangler A, Morgan HE, Goudreau S, Seiler S, Farr D, Wooldridge R, Haley B, Bahrami S, Neufeld S, Mendez C, Alluri P, Rao R, Timmerman RD. Rahimi A, et al. Int J Radiat Oncol Biol Phys. 2022 Jun 1;113(2):475-477. doi: 10.1016/j.ijrobp.2022.02.034. Int J Radiat Oncol Biol Phys. 2022. PMID: 35569485 No abstract available.
Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
Udden SN, Wang Q, Kumar S, Malladi VS, Wu SY, Wei S, Posner BA, Geboers S, Williams NS, Liu Y, Sharma JK, Mani RS, Malladi S, Parra K, Hofstad M, Raj GV, Larios JM, Jagsi R, Wicha MS, Park BH, Gupta GP, Chinnaiyan AM, Chiang CM, Alluri PG. Udden SN, et al. Among authors: alluri pg. JCI Insight. 2022 Sep 8;7(17):e151851. doi: 10.1172/jci.insight.151851. JCI Insight. 2022. PMID: 35881485 Free PMC article.
29 results